CA2952849A1 - Biological characterization of a glatiramer acetate related drug product using mammalian and human cells - Google Patents

Biological characterization of a glatiramer acetate related drug product using mammalian and human cells Download PDF

Info

Publication number
CA2952849A1
CA2952849A1 CA2952849A CA2952849A CA2952849A1 CA 2952849 A1 CA2952849 A1 CA 2952849A1 CA 2952849 A CA2952849 A CA 2952849A CA 2952849 A CA2952849 A CA 2952849A CA 2952849 A1 CA2952849 A1 CA 2952849A1
Authority
CA
Canada
Prior art keywords
expression
level
glatiramer acetate
group
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2952849A
Other languages
English (en)
French (fr)
Inventor
Michael Hayden
Fadi George TOWFIC
Sarah Elisabeth Kolitz
Benjamin James ZESKIND
David Ladkani
Tal Hasson
Liat Hayardeny
Iris Grossman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2952849A1 publication Critical patent/CA2952849A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2952849A 2014-07-01 2015-07-01 Biological characterization of a glatiramer acetate related drug product using mammalian and human cells Abandoned CA2952849A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201462019857P 2014-07-01 2014-07-01
US62/019,857 2014-07-01
US201462020358P 2014-07-02 2014-07-02
US62/020,358 2014-07-02
US201462025953P 2014-07-17 2014-07-17
US62/025,953 2014-07-17
US201462047437P 2014-09-08 2014-09-08
US62/047,437 2014-09-08
US201462078369P 2014-11-11 2014-11-11
US62/078,369 2014-11-11
US201562134245P 2015-03-17 2015-03-17
US62/134,245 2015-03-17
US201562162308P 2015-05-15 2015-05-15
US62/162,308 2015-05-15
PCT/US2015/038901 WO2016004250A2 (en) 2014-07-01 2015-07-01 Biological characterization of a glatiramer acetate related drug product using mammalian and human cells

Publications (1)

Publication Number Publication Date
CA2952849A1 true CA2952849A1 (en) 2016-01-07

Family

ID=55020098

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952849A Abandoned CA2952849A1 (en) 2014-07-01 2015-07-01 Biological characterization of a glatiramer acetate related drug product using mammalian and human cells

Country Status (6)

Country Link
EP (1) EP3164710A4 (es)
CA (1) CA2952849A1 (es)
IL (1) IL249686A0 (es)
TW (1) TW201610169A (es)
UY (1) UY36197A (es)
WO (1) WO2016004250A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053109A1 (en) * 2016-09-14 2018-03-22 Teva Pharmaceutical Industries Ltd. Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157697A2 (en) * 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay

Also Published As

Publication number Publication date
WO2016004250A3 (en) 2016-03-17
UY36197A (es) 2016-01-29
IL249686A0 (en) 2017-02-28
TW201610169A (zh) 2016-03-16
WO2016004250A2 (en) 2016-01-07
EP3164710A4 (en) 2018-04-11
EP3164710A2 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
US11209440B2 (en) T cell balance gene expression, compositions of matters and methods of use thereof
AU2017228502C1 (en) Microbial consortium and uses thereof
US20150361396A1 (en) T cell balance gene expression, compositions of matters and methods of use thereof
US20030148316A1 (en) Methods and compositions relating to plasmacytoid dendritic cells
US20190284531A1 (en) Detection of t cell exhaustion or lack of t cell costimulation and uses thereof
CA2896957A1 (en) Characterizing a glatiramer acetate related drug product
US20160159918A1 (en) Methods for diagnosing and treating immune disease
McKay et al. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies
US20170003277A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
EP4010083A1 (en) Manipulation and use of antigen-specific regulatory t cells
CA2952849A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
Cordiglieri et al. Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies
US20210100897A1 (en) Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof
Park et al. Gene expression profile in patients with axial spondyloarthritis: meta-analysis of publicly accessible microarray datasets
US10385395B2 (en) Diagnostic tools for response to 6-thiopurine therapy
US20230417747A1 (en) Methods and compositions for diagnosing and treating virally-associated disease
WO2018053109A1 (en) Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
US20230241105A1 (en) Methods of use of allergen-specific t cells in allergy and asthma
Mescheriakova et al. Genetics of multiple sclerosis
Acton Systemic Lupus Erythematosus: New Insights for the Healthcare Professional: 2013 Edition
Schilham The auToiMMune 4Q27 locus is associaTed WITh JuvenIle IDIoPAThIC ArThrITIs
Koti et al. Immune-inflammation gene signatures in endometriosis patients
McKay et al. ÔØ Å ÒÙ× Ö ÔØ
Harkensee Microsatellite scanning of the immunogenome for associations with graft-versus-host disease following haematopoietic stem cell transplantation
Petrizzo et al. Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190703